rivastigmine transdermal single-day patch (LY03011) / Luye Group, GeneScience - LARVOL DELTA

Luye Pharma : Grants Gensci Exclusive Commercialization Rights of Rivastigmine Transdermal Patches on China’s Mainland (Market Screener) - "Luye Pharma will receive an upfront payment of RMB 70 million, and the total payment of this agreement is up to RMB 216 million....Luye Pharma Group (Luye Pharma) today announced that its subsidiary Luye Pharma Switzerland AG has entered into an agreement with Changchun GeneScience Pharmaceutical Co., Ltd. (Gensci), under which the company grants Gensci the exclusive, non-transferable, sub-licensable and perpetual commercialization rights of Rivastigmine Single-Day Transdermal Patch (Rivastigmine SD) and Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD) on the Chinese mainland."

Licensing / partnership • CNS Disorders • Dementia